Today, the CFO of Galectin Therapeutics, Jack Callicutt, exercised options of Galectin Therapeutics (NASDAQ: GALT) for $1.95M.
Following Jack Callicutt’s last GALT Sell transaction on August 15, 2014, the stock climbed by 3.2%. In addition to Jack Callicutt, 2 other GALT executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Galectin Therapeutics has an average volume of 917.3K.
The insider sentiment on Galectin Therapeutics has been negative according to 30 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments.
Read More on GALT:
